Matches in Wikidata for { <http://www.wikidata.org/entity/Q37188758> ?p ?o ?g. }
- Q37188758 description "2014 թվականի սեպտեմբերի 10-ին հրատարակված գիտական հոդված" @default.
- Q37188758 description "article científic" @default.
- Q37188758 description "article scientifique" @default.
- Q37188758 description "articolo scientifico" @default.
- Q37188758 description "artigo científico" @default.
- Q37188758 description "artículu científicu espublizáu en 2014" @default.
- Q37188758 description "bilimsel makale" @default.
- Q37188758 description "scientific article published on 10 September 2014" @default.
- Q37188758 description "vedecký článok" @default.
- Q37188758 description "vetenskaplig artikel" @default.
- Q37188758 description "videnskabelig artikel" @default.
- Q37188758 description "vědecký článek" @default.
- Q37188758 description "wetenschappelijk artikel" @default.
- Q37188758 description "wissenschaftlicher Artikel" @default.
- Q37188758 description "наукова стаття, опублікована у вересні 2014" @default.
- Q37188758 description "научни чланак" @default.
- Q37188758 description "مقالة علمية نشرت في 10 سبتمبر 2014" @default.
- Q37188758 name "Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies." @default.
- Q37188758 name "Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies." @default.
- Q37188758 name "Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies." @default.
- Q37188758 type Item @default.
- Q37188758 label "Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies." @default.
- Q37188758 label "Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies." @default.
- Q37188758 label "Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies." @default.
- Q37188758 prefLabel "Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies." @default.
- Q37188758 prefLabel "Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies." @default.
- Q37188758 prefLabel "Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies." @default.
- Q37188758 P1433 Q37188758-3C288770-E232-4772-B8F2-EC3DE77B1518 @default.
- Q37188758 P1476 Q37188758-E6011780-C84A-4A00-A1E9-908D1A6846C9 @default.
- Q37188758 P2093 Q37188758-3C49841F-A393-4F1C-8D12-943E76E74D5C @default.
- Q37188758 P2093 Q37188758-4ED90BD3-7416-450F-A28E-28BCAC0E285F @default.
- Q37188758 P2093 Q37188758-A0590D64-35F9-43D6-8B22-2F2CF1C8DC75 @default.
- Q37188758 P2093 Q37188758-AE75145A-7FE3-41BB-B2C4-79D8F132F052 @default.
- Q37188758 P2093 Q37188758-BA788F65-F3AA-4387-AA3D-DDC8A841AE57 @default.
- Q37188758 P2093 Q37188758-E0FC536B-2746-4AB7-90AA-B2BF87FBEB4F @default.
- Q37188758 P2093 Q37188758-E31E9218-1818-436D-A599-91CE3A5A4F8F @default.
- Q37188758 P2093 Q37188758-E900DF18-6F1A-4958-8651-93DEE55431BC @default.
- Q37188758 P2093 Q37188758-F9F8E89C-C5C2-479E-8C2D-0C606C086D42 @default.
- Q37188758 P2860 Q37188758-0024F25B-9B3A-45FF-963A-18856DAA844C @default.
- Q37188758 P2860 Q37188758-109B69A3-5F30-42C1-BD3A-D24D5D9065C0 @default.
- Q37188758 P2860 Q37188758-110FBC97-AB79-44A5-B01B-8F547FDB0B49 @default.
- Q37188758 P2860 Q37188758-1CF1ACA0-62E2-4199-B97A-17421C33B39D @default.
- Q37188758 P2860 Q37188758-1F9C9437-296A-45BE-A515-BAFF80B5DE79 @default.
- Q37188758 P2860 Q37188758-259AF314-F34C-456D-AF2D-E9F17468E614 @default.
- Q37188758 P2860 Q37188758-26A62DC6-7090-404B-AA81-2240BC353510 @default.
- Q37188758 P2860 Q37188758-2F359077-96C8-4E14-9024-788928A75DDD @default.
- Q37188758 P2860 Q37188758-310CF59B-88C6-4A5A-B71F-D1B9F0F4C307 @default.
- Q37188758 P2860 Q37188758-3B8505EA-13E3-4AEB-B91C-E6DF13F59632 @default.
- Q37188758 P2860 Q37188758-43599650-FE09-438B-A279-10A10EFB9EB5 @default.
- Q37188758 P2860 Q37188758-59C9A6DF-1456-4753-8AF8-930FF1B8EEDF @default.
- Q37188758 P2860 Q37188758-6A49CFA8-27E7-4FED-BE51-4CBBADAE1E7C @default.
- Q37188758 P2860 Q37188758-6A4CA9A0-63B5-47AC-B336-9465E09F36D4 @default.
- Q37188758 P2860 Q37188758-78DD8367-A415-4C4E-B489-5FC1E0E92A8C @default.
- Q37188758 P2860 Q37188758-8EB46A69-5326-49BE-9C64-D0216472E900 @default.
- Q37188758 P2860 Q37188758-B4F14F6C-4D7A-4C9E-B17B-8F2F0391C040 @default.
- Q37188758 P2860 Q37188758-BD4FD82A-8686-4D73-8A73-54401AA9F4FB @default.
- Q37188758 P2860 Q37188758-BEA86F3D-B093-42A2-BA43-F32F7E5671BB @default.
- Q37188758 P2860 Q37188758-E2CE8B64-AE65-4994-A69D-7B93D4F6B1C3 @default.
- Q37188758 P304 Q37188758-25972740-AD08-48C7-B628-CB8E59B7BD72 @default.
- Q37188758 P31 Q37188758-31BD2230-90CD-4276-B7FE-D083DDF84C29 @default.
- Q37188758 P356 Q37188758-EB2BDB55-BF13-4892-88AF-3F49D3020102 @default.
- Q37188758 P407 Q37188758-7D04E61A-EF5D-428C-997A-8AA4C7183C09 @default.
- Q37188758 P433 Q37188758-C3EC5D44-5AC9-4CBD-B01C-D20C518474B2 @default.
- Q37188758 P478 Q37188758-ADA46520-826D-4F70-9787-F4E5184664EE @default.
- Q37188758 P50 Q37188758-20E66C4E-0195-4D8D-88ED-728CFCEEC6F7 @default.
- Q37188758 P50 Q37188758-6657806F-4B4C-4F49-A230-508C6A6F221E @default.
- Q37188758 P577 Q37188758-CB8998C3-9876-4E11-BABE-9B462BF48BCF @default.
- Q37188758 P5875 Q37188758-19A52ECA-6059-4F5B-B557-044C34D8E1D0 @default.
- Q37188758 P698 Q37188758-87E6B3F7-F36F-4476-AA9F-71AC9AEA4CF1 @default.
- Q37188758 P921 Q37188758-A2A378CF-5D2F-447D-B9B7-A3B48D74D61E @default.
- Q37188758 P921 Q37188758-B3EE278F-9325-446D-9493-B3258088A17D @default.
- Q37188758 P932 Q37188758-9D57E0CF-CC4D-4610-8835-FB234E522762 @default.
- Q37188758 P356 MDU441 @default.
- Q37188758 P698 25210016 @default.
- Q37188758 P1433 Q326122 @default.
- Q37188758 P1476 "Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies" @default.
- Q37188758 P2093 "B Neyns" @default.
- Q37188758 P2093 "C Konto" @default.
- Q37188758 P2093 "C Lebbé" @default.
- Q37188758 P2093 "J D Wolchok" @default.
- Q37188758 P2093 "K Harmankaya" @default.
- Q37188758 P2093 "L Cykowski" @default.
- Q37188758 P2093 "M B McHenry" @default.
- Q37188758 P2093 "O Hamid" @default.
- Q37188758 P2093 "S J O'Day" @default.
- Q37188758 P2860 Q27861062 @default.
- Q37188758 P2860 Q28131634 @default.
- Q37188758 P2860 Q29614803 @default.
- Q37188758 P2860 Q30890582 @default.
- Q37188758 P2860 Q33845393 @default.
- Q37188758 P2860 Q34149569 @default.
- Q37188758 P2860 Q34507305 @default.
- Q37188758 P2860 Q34614776 @default.
- Q37188758 P2860 Q34616628 @default.
- Q37188758 P2860 Q35584299 @default.
- Q37188758 P2860 Q35617517 @default.
- Q37188758 P2860 Q35871798 @default.
- Q37188758 P2860 Q37542216 @default.
- Q37188758 P2860 Q37681718 @default.
- Q37188758 P2860 Q38012057 @default.